State of Alaska Department of Revenue reduced its stake in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.2% ...

The stock market heads into an interesting round of earnings, led by Walmart, RIvian, and a key Warren Buffett stock.

Potential Trend of GMED Stock Following the News Since the announcement on Feb. 6, shares of Globus Medical have dropped 0.6%, closing at $87.38 yesterday. On a positive note, the company is ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

Finally, Royal Bank of Canada upped their target price on Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. Four equities ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

EST Globus Medical (GMED) to acquire Nevro (NVRO) for $5.85 per shareMaximize Your Portfolio with Data Driven Insights:Leverage the power ...

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...